This AI-focused health stock is a buy that can rally nearly 50%, BTIG says

This AI-focused health stock is a buy that can rally nearly 50%, BTIG says

Analyst Mark Massaro initiated coverage on the stock with a buy rating.

Tempus AI Gets Bullish Boost from BTIG on Data Strength, Expansion Moves

BTIG just kicked off coverage on Tempus AI (TEM, Financial) with a Buy rating and a $60 price target — suggesting nearly 48% upside from where the stock trades now. Analyst Mark Massaro called the company’s AI-driven data operations a “significant free call option” for investors, pointing to its potential for long-term growth. Massaro described Tempus as a fast-growing tech company in the precision medicine space. It’s starting with oncology but…